Related Experiment Video
Updated: Jul 14, 2025
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
Propensity Score Matching Analysis Comparing the Efficacy and Steroid Tapering Benefit of Extracorporeal
Igor Novitzky-Basso1, Christopher Patriquin2, Swe Mar Linn1
1Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Faculty of Medicine, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Insights
Extracorporeal photopheresis (ECP) significantly improves survival and reduces treatment failure in chronic graft-versus-host disease (cGVHD) patients refractory to standard therapies. ECP also enables faster corticosteroid tapering compared to best available therapy (BAT).
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HCT).
- Approximately 50% of chronic GVHD (cGVHD) patients are refractory to first-line corticosteroid therapy.
- Effective salvage therapies are crucial for improving outcomes in refractory cGVHD.
Purpose of the Study:
- To compare treatment outcomes of extracorporeal photopheresis (ECP) versus best available therapy (BAT) in patients with third-line or beyond cGVHD.
- To evaluate the efficacy of ECP in improving survival and enabling steroid reduction in refractory cGVHD.
Main Methods:
- Propensity score matching (PSM) was used to balance patient characteristics between ECP and BAT groups.
- Key factors adjusted for included GVHD severity, prior acute GVHD, and baseline corticosteroid dose.
- Treatment outcomes, including failure-free survival (FFS) and overall survival (OS), were compared between matched cohorts.
Main Results:
- In the PSM cohort (n=62), ECP demonstrated significantly higher 12-month FFS (70.1% vs. 32.5%, P < .0001) and OS (93.1% vs. 68.1%, P = .0249) compared to BAT.
- Multivariate analysis confirmed superior FFS and OS for ECP.
- ECP treatment led to faster corticosteroid tapering and higher rates of prednisone discontinuation within the first six months compared to BAT.
Conclusions:
- ECP is a superior third-line or beyond treatment for cGVHD compared to BAT, offering improved survival outcomes.
- ECP facilitates more effective corticosteroid reduction in refractory cGVHD patients.
- These findings support the use of ECP as an effective salvage therapy for steroid-refractory cGVHD.
Abstract:
Graft-versus host disease (GVHD) is one of the major limitations to allogeneic hematopoietic stem cell transplantation (HCT). Although corticosteroids with calcineurin inhibitors are established first line-therapy for chronic graft-versus-host disease (cGVHD), approximately one-half of cGVHD patients are refractory to corticosteroid therapy. The goal of the present study was to compare treatment outcomes of patients treated with extracorporeal photopheresis (ECP) and best available therapy (BAT) as third-line or beyond treatment for cGVHD. Using propensity score matching (PSM), treatment outcomes were compared between ECP-treated patients (n = 74) and a historical cohort of cGVHD patients treated with BAT (n = 132). By adjusting for unbalanced risk factors between the groups, including GVHD severity at the start of therapy, acute GVHD history, and baseline corticosteroid dose, 62 patients were balanced and selected for PSM. In the PSM cohort, the ECP group showed a 12-month failure-free survival (FFS) rate of 70.1% versus 32.5% in the BAT group (P < .0001; hazard rate [HR], .214), and 93.1% 12 months' overall survival (OS) rate of 93.1% versus 68.1% in the BAT group (P = .0249; HR, .3811); multivariate analysis confirmed ECP's superior FFS and OS compared with BAT. Generalized linear model analysis showed faster tapering of corticosteroids and higher rates of prednisone discontinuation in the ECP versus BAT PSM groups in the first 6 months. The ECP group also had a higher percentage of prednisone discontinuation, by 6% at month 0, by 14.9% at month 3, and by 22.5% at month 6. The current study demonstrates superior FFS, OS, and steroid tapering efficacy for ECP compared with BAT as third-line therapy or beyond in cGVHD patients.
